Dr. Reddy's Laboratories Limited has announced a temporary delay in the commercial supply of semaglutide after identifying quality issues in certain product batches, as per the exchange filings.
The company said some batches were found to be out of specification due to an issue associated with the Active Pharmaceutical Ingredient (API) used in the product.
Dr. Reddy's stated that it is investigating the root cause of the issue and has initiated appropriate measures to ensure product quality.
Until the investigation is completed and the issue is resolved, commercial supplies of semaglutide will remain delayed for a certain period. The company has not specified the timeline for resuming supplies.
The company clarified that the issue has no impact on patient safety.
It also stated that its existing global regulatory filings for the product remain unaffected and reaffirmed its commitment to ensuring reliable global supplies of the metabolic therapy.
Dr. Reddy's Laboratories is a global pharmaceutical company engaged in the development, manufacturing and marketing of generic medicines, biosimilars, active pharmaceutical ingredients (APIs) and proprietary products.
The company has a presence across major international markets and offers medicines in therapeutic areas including oncology, gastroenterology, cardiovascular diseases, diabetes and pain management.
Read More: Marksans Pharma Share Price in Focus; To Acquire Germany-Based ABCnow GmbH to Expand European Presence!
As of 09 July 2026, at 10:40 AM, Dr. Reddy's Laboratories Limited share price was trading at ₹1,301.10 per share, reflecting a decline of 3.55% from the previous trading session.
Dr. Reddy's has temporarily delayed commercial supplies of semaglutide while addressing an API-related quality issue identified in certain batches. The company is investigating the cause and implementing corrective measures, while confirming that patient safety remains unaffected.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 9, 2026, 12:59 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
